Zemcelpro® (dorocubicel), also known as the UM171 cell therapy, receives conditional authorization from the European Commission for the treatment of certain hematological malignancies. Building on this status, FarmaMondo has been granted distribution rights for Zemcelpro® in three territories: Argentina, Hong Kong, and Singapore. The announcements describe this as a distribution agreement covering those markets and refer to the product under both its trade name and its scientific designation (UM171). All sources state that the European Commission authorization is conditional and is specifically for particular types of malignant hematologic diseases, while the distribution rights are held by FarmaMondo for the named regions. The articles do not provide additional clinical details, pricing, or regulatory outcomes beyond the conditional European authorization and the distribution rights. The reporting is limited to the agreement’s existence and the regulatory context, presenting the expansion of commercial availability in the stated countries and territories through FarmaMondo’s distribution activities.